- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Pharmala Biotech Holdings Inc: Pharmala talks revenue slowdown; NR omits Q1 P&L | 1 | Stockwatch | ||
| Mi | PharmAla Biotech: PharmAla Issues Q1 Financial Statements | 254 | GlobeNewswire (Europe) | TORONTO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| PHARMALA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 21.01. | Pharmala Biotech Holdings Inc: Pharmala to supply MDMA trial material for licence | 1 | Stockwatch | ||
| 20.01. | PharmAla Biotech: PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel | 1 | GlobeNewswire (USA) | ||
| 21.12.24 | Pharmala Biotech Holdings Inc: Pharmala Biotech talks 2024 revenue, closes financing | 1 | Stockwatch | ||
| 20.12.24 | PharmAla Biotech: PharmAla Issues Audited Financial Statements, Completes Continuance to Ontario, and Closes Private Placement | 2 | GlobeNewswire (USA) | ||
| 13.12.24 | PharmAla Biotech: PharmAla Announces Private Placement | 3 | GlobeNewswire (USA) | ||
| 14.11.24 | PharmAla Biotech: PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License | 2 | GlobeNewswire (USA) | ||
| 07.11.24 | PharmAla Biotech: PharmAla to supply LaNeo MDMA for Clinical Trial at Yale | 2 | GlobeNewswire (USA) | ||
| 21.10.24 | Pharmala Biotech Holdings Inc: Pharmala Biotech to supply MDMA to Mt. Sinai hospital | 4 | Stockwatch | ||
| 21.10.24 | PharmAla Biotech: PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA | 1 | GlobeNewswire (USA) | ||
| 08.10.24 | Pharmala Biotech Holdings Inc: Pharmala Biotech to supply MDMA to University of Texas | 2 | Stockwatch | ||
| 08.10.24 | PharmAla Biotech To Supply University Of Texas, San Antonio For Clinical Trial | 4 | Benzinga.com | ||
| 08.10.24 | PharmAla Biotech: PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo MDMA | 1 | GlobeNewswire (USA) | ||
| 02.10.24 | Pharmala Biotech Holdings Inc: Pharmala Biotech to supply MDMA to Harvard's Maclean | 1 | Stockwatch | ||
| 02.10.24 | PharmAla Biotech To Supply MDMA For Harvard's Maclean Hospital Clinical Trial | 2 | Benzinga.com | ||
| 02.10.24 | PharmAla to supply Harvard Medical School trial with MDMA | 4 | The Market Herald Canada | ||
| 02.10.24 | PharmAla Biotech: PharmAla to supply Harvard Medical School's Maclean Hospital with LaNeo MDMA | 1 | GlobeNewswire (USA) | ||
| 11.09.24 | Pharmala Biotech Holdings Inc: Pharmala to supply MDMA for Johns Hopkins trial | 1 | Stockwatch | ||
| 11.09.24 | PharmAla Biotech Partners With Johns Hopkins University For MDMA Clinical Trials, Terminates Red Light Holland Contract | 2 | Benzinga.com |
Seite:
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 57,19 | 0,00 % | Tempus AI's Options Frenzy: What You Need to Know | ||
| EVOTEC | 8,580 | +5,66 % | Commerzbank, Deutsche Bank, Evotec, Infineon, Nvidia, Valneva - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| TECTONIC THERAPEUTIC | 54,73 | 0,00 % | Pre-market Movers: China Liberal Education, CARGO Therapeutics, Tectonic Therapeutic, Silexion Therapeutics, Banzai International | SANDY SPRINGS (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green Tectonic Therapeutic, Inc. (TECX) is up over... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 13,670 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million | Preliminary unaudited product revenue for the fourth quarter of 2024 is expected to be approximately $63 million, up approximately 366% vs. Q4 2023 and 41% vs. Q3 2024Preliminary unaudited product... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,690 | 0,00 % | How Is The Market Feeling About Recursion Pharmaceuticals? | ||
| BIONTECH | 116,60 | +0,34 % | BioNTech Aktie: Break über 131 Dollar könnte heftige Kursrallye auslösen | Die BioNTech Aktie legte gestern an der NASDAQ auf Schlusskursbasis mehr als sechs Prozent auf 122,12 Dollar zu und konnte ein kleines Kaufsignal generieren. Durch den Anstieg über das Gap bei 118,74/120... ► Artikel lesen | |
| MODERNA | 40,315 | -3,59 % | Moderna erhält den Zuschlag für die Belieferung der Europäischen Union mit seinem COVID-19-mRNA-Impfstoff | Die Vereinbarung bietet den teilnehmenden Ländern die Chance, ihre Versorgung mit dem COVID-19-mRNA-Impfstoff zu
diversifizieren und Zugang zu diesem Impfstoff in Form einer Fertigspritze zu... ► Artikel lesen | |
| CG ONCOLOGY | 30,150 | -0,30 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates | - Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature... ► Artikel lesen | |
| CARGO THERAPEUTICS | 3,390 | 0,00 % | Safety Risk Sinks Cargo Therapeutics' Cancer Cell Therapy Prospect, Leading to 50% Staff Cut | ||
| 89BIO | 9,650 | +10,54 % | 89bio, Inc. - 8-K, Current Report | ||
| BB BIOTECH | 42,600 | +2,16 % | EQS-News: BB BIOTECH AG: Vorläufige Jahresergebnisse 2024 und Dividendenvorschlag | EQS-News: BB BIOTECH AG
/ Schlagwort(e): Jahresergebnis/Dividende
BB Biotech: Vorläufige Jahresergebnisse 2024 und Dividendenvorschlag
24.01.2025 / 07:00 CET/CEST
Für... ► Artikel lesen | |
| IMMUNOME | 10,510 | 0,00 % | Immunome Inc. - 8-K, Current Report | ||
| VIR BIOTECHNOLOGY | 10,290 | 0,00 % | Vir Biotechnology, Inc. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 22,320 | +3,14 % | Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock? | ||
| AVIDITY BIOSCIENCES | 32,630 | +2,10 % | Avidity Biosciences, Inc.: Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 | Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025
On track to complete enrollment in del-desiran... ► Artikel lesen |
PHARMALA BIOTECH HOLDINGS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMALA BIOTECH HOLDINGS INC finden Sie auf Wallstreet Online.
